Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma

Table 3

The influence of MMP genotypes on time to progression and overall survival in MPM patients, adjusted for clinical variables.

Gene	Genotype	Time to progression	HR (95% CI)		Overall survival	HR (95% CI)
		Median (25%–75%)			Median (25%–75%)
MMP2
rs243865	CC	8.83 (6.43–15.03)	Ref.		17.43 (10.60–27.27)	Ref.
	CT	10.17 (6.00–16.33)	0.88 (0.63–1.22)	0.437	17.47 (9.47–31.17)	0.96 (0.68–1.36)	0.826
	TT	14.97 (8.20–44.57)	0.54 (0.17–1.75)	0.305	30.00 (22.03–30.00)	0.44 (0.11–1.81)	0.255
	CT + TT	10.20 (6.27–16.33)	0.85 (0.61–1.18)	0.334	18.07 (9.63–31.17)	0.92 (0.66–1.30)	0.653
rs243849	CC	9.87 (6.13–16.67)	Ref.		19.10 (9.83–28.13)	Ref.
	CT	8.67 (6.67–14.30)	1.30 (0.91–1.86)	0.144	16.23 (10.80–29.03)	1.26 (0.86–1.85)	0.227
	TT	7.33 (3.27–11.80)	2.16 (1.02–4.55)	0.043	17.63 (7.33–36.73)	1.18 (0.51–2.72)	0.698
	CT + TT	8.67 (6.60–14.30)	1.38 (0.98–1.94)	0.064	16.63 (10.80–30.27)	1.25 (0.87–1.80)	0.225
rs7201	AA	9.27 (6.37–16.93)	Ref.		16.23 (10.63–28.03)	Ref.
	AC	10.00 (6.73–15.03)	0.87 (0.61–1.24)	0.441	19.30 (10.80–30.00)	0.89 (0.62–1.29)	0.547
	CC	8.00 (5.50–12.63)	1.15 (0.73–1.80)	0.551	14.20 (9.23–26.17)	1.20 (0.74–1.95)	0.467
	AC + CC	9.80 (6.43–14.57)	0.93 (0.67–1.30)	0.684	18.07 (9.63–29.03)	0.96 (0.67–1.36)	0.803
MMP9
rs17576	AA	9.27 (6.13–13.53)	Ref.		13.57 (9.83–23.90)	Ref.
	AG	10.73 (6.80–18.47)	0.84 (0.60–1.17)	0.303	21.20 (12.17–32.53)	0.72 (0.50–1.03)	0.070
	GG	8.50 (6.00–16.67)	1.17 (0.69–1.98)	0.558	16.63 (8.27–26.60)	0.96 (0.54–1.68)	0.881
	AG + GG	10.00 (6.67–16.90)	0.89 (0.65–1.23)	0.478	19.30 (11.33–31.17)	0.76 (0.54–1.06)	0.106
rs2250889	CC	10.03 (6.73–16.67)	Ref.		19.10 (11.33–30.00)	Ref.
	CG	6.07 (4.07–7.90)	2.32 (1.34–4.03)	0.003	9.23 (4.53–14.20)	2.52 (1.42–4.46)	0.002
rs17577	GG	10.00 (6.60–16.33)	Ref.		18.07 (10.60–28.30)	Ref.
	GA	8.33 (5.50–14.57)	1.20 (0.84–1.72)	0.319	17.63 (9.47–32.87)	0.82 (0.56–1.20)	0.311
	AA	8.83 (8.00–19.43)	1.02 (0.32–3.25)	0.977	13.50 (9.97–25.93)	1.58 (0.49–5.04)	0.444
	GA + AA	8.50 (5.53–14.57)	1.19 (0.84–1.68)	0.339	17.63 (9.63–32.53)	0.85 (0.59–1.24)	0.403
rs20544	CC	7.53 (5.53–11.53)	Ref.		13.50 (8.13–21.20)	Ref.
	CT	10.93 (7.37–19.97)	0.60 (0.40–0.90)	0.014	20.67 (11.33–32.53)	0.59 (0.39–0.91)	0.018
	TT	9.40 (6.27–14.30)	0.67 (0.43–1.03)	0.069	15.40 (10.80–25.67)	0.70 (0.44–1.11)	0.132
	CT + TT	10.13 (6.73–16.20)	0.62 (0.43–0.92)	0.016	19.30 (10.80–31.17)	0.63 (0.42–0.95)	0.025
MMP14
rs1042703	TT	9.27 (6.67–16.33)	Ref.		17.50 (9.97–29.13)	Ref.
	TC	10.17 (6.27–14.53)	1.36 (0.94–1.96)	0.100	19.30 (9.47–29.03)	1.25 (0.87–1.81)	0.229
	CC	8.70 (5.13–16.20)	2.09 (1.06–4.12)	0.032	12.70 (7.07–20.60)	2.14 (1.12–4.06)	0.020
	TC + CC	10.17 (6.03–14.97)	1.44 (1.01–2.03)	0.042	17.63 (8.30–28.30)	1.36 (0.97–1.92)	0.076
rs1042704	GG	9.80 (6.73–14.90)	Ref.		17.50 (10.80–31.17)	Ref.
	GA	8.30 (5.70–16.20)	1.05 (0.74–1.49)	0.780	17.47 (9.10–24.23)	1.40 (0.98–2.00)	0.068
	AA	7.87 (6.00–16.90)	0.90 (0.45–1.82)	0.777	20.27 (13.57–25.93)	1.22 (0.59–2.53)	0.598
	GA + AA	8.30 (5.93–16.90)	1.03 (0.74–1.42)	0.881	18.07 (9.63–24.57)	1.37 (0.97–1.92)	0.072
rs743257	CC	9.87 (7.07–14.07)	Ref.		13.50 (9.97–27.27)	Ref.
	CT	9.40 (5.97–19.43)	1.08 (0.72–1.64)	0.700	15.40 (6.80–28.13)	0.98 (0.65–1.49)	0.931
	TT	9.70 (6.60–14.53)	1.15 (0.75–1.76)	0.535	20.17 (12.53–31.17)	0.87 (0.56–1.36)	0.544
	CT + TT	9.43 (6.07–16.33)	1.11 (0.76–1.63)	0.588	19.30 (9.83–30.27)	0.93 (0.63–1.37)	0.722